{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:17:10Z","timestamp":1791573430945,"version":"4.3.4"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T00:00:00Z","timestamp":1653091200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T00:00:00Z","timestamp":1653091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s10067-022-06205-z","type":"journal-article","created":{"date-parts":[[2022,5,21]],"date-time":"2022-05-21T10:02:39Z","timestamp":1653127359000},"page":"2961-2966","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Real-world evidence of the effectiveness and safety of generic tofacitinib in rheumatoid arthritis patients: a retrospective, single-centre analysis from Western India"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3548-9956","authenticated-orcid":false,"given":"Sanat","family":"Phatak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditya","family":"Khenat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mansi","family":"Malandkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjiv","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,21]]},"reference":[{"key":"6205_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2147\/TCRM.S138677","volume":"14","author":"P Kawalec","year":"2017","unstructured":"Kawalec P, \u015aladowska K, Malinowska-Lipie\u0144 I, Brzostek T, K\u00f3zka M (2017) European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib. Ther Clin Risk Manag 14:15\u201329","journal-title":"Ther Clin Risk Manag"},{"key":"6205_CR2","doi-asserted-by":"crossref","unstructured":"Burmester GR, Blanco R, Charles-Schoeman C et al (2013) ORAL Step investigators. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 381:451\u201360","DOI":"10.1016\/S0140-6736(12)61424-X"},{"key":"6205_CR3","doi-asserted-by":"crossref","unstructured":"Fleischmann R, Mysler E, Hall S et al (2017) ORAL Strategy investigators. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial. Lancet 390:457\u2013468","DOI":"10.1016\/S0140-6736(17)31618-5"},{"key":"6205_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000491","volume":"3","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Wollenhaupt J, Takiya L et al (2017) Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies. RMD Open 3:e000491","journal-title":"RMD Open"},{"key":"6205_CR5","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79:685\u2013699","journal-title":"Ann Rheum Dis"},{"issue":"24","key":"6205_CR6","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.2146\/news120088","volume":"69","author":"K Traynor","year":"2012","unstructured":"Traynor K (2012) FDA approves tofacitinib for rheumatoid arthritis. Am J Health Syst Pharm 69(24):2120. https:\/\/doi.org\/10.2146\/news120088","journal-title":"Am J Health Syst Pharm"},{"key":"6205_CR7","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/1756-185X.13513","volume":"22","author":"CS Lau","year":"2019","unstructured":"Lau CS, Chia F, Dans L et al (2019) 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis. Int J Rheum Dis 22:357\u2013375","journal-title":"Int J Rheum Dis"},{"key":"6205_CR8","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1017\/S0007114508207221","volume":"102","author":"EC Rush","year":"2009","unstructured":"Rush EC, Freitas I, Plank LD (2009) Body size, body composition and fat distribution: comparative analysis of European, Maori, Pacific Island and Asian Indian adults. Br J Nutr 102:632\u2013641. https:\/\/doi.org\/10.1017\/S0007114508207221","journal-title":"Br J Nutr"},{"key":"6205_CR9","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1111\/1756-185X.13853","volume":"23","author":"A Chopra","year":"2020","unstructured":"Chopra A, Shobha V, Chandrashekara S et al (2020) Tofacitinib in the treatment of Indian patients with rheumatoid arthritis: a post hoc analysis of efficacy and safety in phase 3 and long-term extension studies over 7 years. Int J Rheum Dis 23:882\u2013897","journal-title":"Int J Rheum Dis"},{"key":"6205_CR10","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/jrsm.1207","volume":"7","author":"M Egger","year":"2016","unstructured":"Egger M, Moons KG, Fletcher C (2016) GetReal Workpackage 4 GetReal: from efficacy in clinical trials to relative effectiveness in the real world. Res Synth Methods. 7:278\u201381","journal-title":"Res Synth Methods."},{"key":"6205_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.2147\/POR.S137701","volume":"8","author":"MS Barnish","year":"2017","unstructured":"Barnish MS, Turner S (2017) The value of pragmatic and observational studies in health care and public health. Pragmat Obs Res 8:49\u201355","journal-title":"Pragmat Obs Res"},{"key":"6205_CR12","doi-asserted-by":"crossref","unstructured":"Fleischmann R, Kremer J, Cush J, et al (2012) ORAL Solo Investigators. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med   9;367:495\u2013507","DOI":"10.1056\/NEJMoa1109071"},{"key":"6205_CR13","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/acr2.11232","volume":"3","author":"JM Kremer","year":"2021","unstructured":"Kremer JM, Bingham CO 3rd, Cappelli LC et al (2021) Post-approval comparative safety study of tofacitinib and biological disease-modifying antirheumatic drugs: 5-year results from a United States-based Rheumatoid Arthritis Registry. ACR Open Rheumatol 3:173\u2013184","journal-title":"ACR Open Rheumatol"},{"key":"6205_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177057","volume":"12","author":"N Iwamoto","year":"2017","unstructured":"Iwamoto N, Tsuji S, Takatani A et al (2017) Efficacy and safety at 24 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis. PLoS ONE 12:e0177057","journal-title":"PLoS ONE"},{"key":"6205_CR15","doi-asserted-by":"crossref","unstructured":"Harnett J, Gerber R, Gruben D, Koenig AS, Chen C (2016) Evaluation of real-world experience with tofacitinib compared with adalimumab, etanercept, and abatacept in RA patients with 1 previous biologic DMARD: data from a U.S. Administrative Claims Database. J Manag Care Spec Pharm 22:1457\u20131471","DOI":"10.18553\/jmcp.2016.22.12.1457"},{"key":"6205_CR16","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.3390\/jcm8101548","volume":"8","author":"RB Mueller","year":"2019","unstructured":"Mueller RB, Hasler C, Popp F et al (2019) Effectiveness, tolerability, and safety of tofacitinib in rheumatoid arthritis: a retrospective analysis of real-world data from the St. Gallen and Aarau cohorts. J Clin Med. 8:1548","journal-title":"J Clin Med."},{"key":"6205_CR17","doi-asserted-by":"publisher","first-page":"663","DOI":"10.2169\/internalmedicine.9341-17","volume":"57","author":"S Mori","year":"2018","unstructured":"Mori S, Yoshitama T, Ueki Y (2018) Tofacitinib therapy for rheumatoid arthritis: a direct comparison study between biologic-na\u00efve and experienced patients. Intern Med 57:663\u2013670","journal-title":"Intern Med"},{"key":"6205_CR18","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.mayocp.2020.01.039","volume":"95","author":"F Wang","year":"2020","unstructured":"Wang F, Sun L, Wang S et al (2020) Efficacy and safety of tofacitinib, baricitinib, and upadacitinib for rheumatoid arthritis: a systematic review and meta-analysis. Mayo Clin Proc 95:1404\u20131419","journal-title":"Mayo Clin Proc"},{"key":"6205_CR19","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1136\/annrheumdis-2015-207319","volume":"75","author":"KL Winthrop","year":"2016","unstructured":"Winthrop KL, Park SH, Gul A et al (2016) Tuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritis. Ann Rheum Dis 75:1133\u20131138","journal-title":"Ann Rheum Dis"},{"key":"6205_CR20","doi-asserted-by":"crossref","unstructured":"Guimar\u00e3es PO, Quirk D, Furtado RH et al (2021) STOP-COVID Trial Investigators. Tofacitinib in patients hospitalized with Covid-19 pneumonia. N Engl J Med 385:406\u2013415","DOI":"10.1056\/NEJMoa2101643"},{"key":"6205_CR21","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00296-019-04303-x","volume":"39","author":"DS Novikova","year":"2019","unstructured":"Novikova DS, Udachkina HV, Markelova EI et al (2019) Dynamics of body mass index and visceral adiposity index in patients with rheumatoid arthritis treated with tofacitinib. Rheumatol Int 39:1181\u20131189","journal-title":"Rheumatol Int"},{"key":"6205_CR22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/art.38894","volume":"67","author":"A Souto","year":"2015","unstructured":"Souto A, Salgado E, Maneiro JR, Mera A, Carmona L, G\u00f3mez-Reino JJ (2015) Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis. Arthritis Rheumatol 67:117\u2013127","journal-title":"Arthritis Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06205-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-022-06205-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-022-06205-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T08:02:05Z","timestamp":1744185725000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-022-06205-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,21]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["6205"],"URL":"https:\/\/doi.org\/10.1007\/s10067-022-06205-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2022.04.08.22273582","asserted-by":"object"}]},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,21]]},"assertion":[{"value":"1 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"De-identified data will be available with Dr S N Amin for sharing after publication and will be shared depending on the merit and prior approval of proposals. Data requests can be made to drsnamin@gmail.com.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data sharing"}}]}}